계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Novacea
About
treatment of cancer
- 11 - 50
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $35M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 11 - 50
- Operating Status
- Active
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 8, 2004 | Series C | $35M | 1 | — | — | Detail |
| Nov 5, 2002 | Series B | $36M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Versant Ventures
|
— | Series C |
